15-522 Phase I
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)
Search Cancer Clinical Trials
The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
13 results
19-893 Phase I
A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-93269, A BCMA X CD3 T CELL ENGAGING ANTIBODY, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (View details on clinicaltrial.gov)
21-245 Phase II
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma (View details on clinicaltrial.gov)
22-448 Phase II
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (View details on clinicaltrial.gov)
22-166 Phase II
A Phase 1B/2, Open Label Umbrella Study of Elranatamab (PF-06863135), A B-CELL Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma (View details on clinicaltrial.gov)
19-054 Phase II
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety And Tolerability, Pharmacokinetics And Preliminary Efficacy of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (View details on clinicaltrial.gov)
18-604 Phase II
A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2). (View details on clinicaltrial.gov)
20-518 Phase I
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)
22-533 Phase II
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (View details on clinicaltrial.gov)
20-074 Phase II
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (View details on clinicaltrial.gov)
Showing 1 - 10 of 13 results